X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Novartis with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs MYLAN (US) - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   MYLAN
EQUITY SHARE DATA
    NOVARTIS
Mar-18
MYLAN
Dec-14
NOVARTIS/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7584,097-   
Low Rs5792,887-   
Sales per share (Unadj.) Rs228.41,402.5-  
Earnings per share (Unadj.) Rs31.7169.0-  
Cash flow per share (Unadj.) Rs32.8272.0-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.1697.2-  
Shares outstanding (eoy) m24.69378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x2.92.5 117.6%   
Avg P/E ratio x21.120.7 101.9%  
P/CF ratio (eoy) x20.412.8 158.9%  
Price / Book Value ratio x2.25.0 44.9%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,5051,321,265 1.2%   
No. of employees `0000.725.0 2.7%   
Total wages/salary Rs m1,4450-   
Avg. sales/employee Rs Th8,441.321,226.9 39.8%   
Avg. wages/employee Rs Th2,163.60-   
Avg. net profit/employee Rs Th1,173.12,557.1 45.9%   
INCOME DATA
Net Sales Rs m5,639530,673 1.1%  
Other income Rs m1,718-3,093 -55.5%   
Total revenues Rs m7,357527,580 1.4%   
Gross profit Rs m-63131,981 -0.0%  
Depreciation Rs m2538,976 0.1%   
Interest Rs m5522,890 0.2%   
Profit before tax Rs m1,57567,022 2.4%   
Minority Interest Rs m0-275 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7922,818 28.1%   
Profit after tax Rs m78463,928 1.2%  
Gross profit margin %-1.124.9 -4.5%  
Effective tax rate %50.34.2 1,195.1%   
Net profit margin %13.912.0 115.4%  
BALANCE SHEET DATA
Current assets Rs m9,522466,532 2.0%   
Current liabilities Rs m3,296364,734 0.9%   
Net working cap to sales %110.419.2 575.5%  
Current ratio x2.91.3 225.8%  
Inventory Days Days3778 46.9%  
Debtors Days Days28107 26.5%  
Net fixed assets Rs m46122,770 0.0%   
Share capital Rs m12318,766 0.7%   
"Free" reserves Rs m7,2130-   
Net worth Rs m7,336263,797 2.8%   
Long term debt Rs m0394,086 0.0%   
Total assets Rs m11,1051,062,549 1.0%  
Interest coverage x29.53.9 750.6%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.50.5 101.7%   
Return on assets %7.68.2 92.5%  
Return on equity %10.724.2 44.1%  
Return on capital %22.213.6 163.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-3,5700-   
CASH FLOW
From Operations Rs m1,61069,757 2.3%  
From Investments Rs m687-55,013 -1.2%  
From Financial Activity Rs m-2,677-18,381 14.6%  
Net Cashflow Rs m-380-3,636 10.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.74 Rs / USD

Compare NOVARTIS With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: TORRENT PHARMA  PANACEA BIOTECH  J.B.CHEMICALS  SHASUN PHARMA  WOCKHARDT LTD.  



Today's Market

Of IPOs, LIC-IDBI Bank Deal, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed marginally higher on Friday last week. All sectoral indices traded in green, with stocks in the IT sector and stocks in the pharma sector, leading the gains.

Related Views On News

NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Sintex's Auditor Resigns. How You Can Protect Yourself from Such Stocks(The 5 Minute Wrapup)

Jul 20, 2018

While the attack on the bad corporate governance is an overhang in the near term...this can be a game-changer in the years to come.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

PPF v/s Mutual Funds: Which Is Better?(Outside View)

Jul 10, 2018

PersonalFN highlights the key points of distinction between PPF and mutual funds.

ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)

Jul 11, 2018

PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 20, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - TORRENT PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS